50
Participants
Start Date
January 8, 2018
Primary Completion Date
December 12, 2023
Study Completion Date
December 12, 2023
Atorvastatin
Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
Placebo oral capsule
Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
Mayo Clinic in Rochester, Rochester
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Mayo Clinic
OTHER